← Back to Search

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

Phase 2

Waitlist Available

Research Sponsored by Integrative Research Laboratories AB

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to end of treatment (week 12)

Summary

This trial is testing mesdopetam, a medication, to help people with Parkinson's disease. The goal is to see if it can increase the time patients feel well without experiencing troublesome movements. Patients will take the medication for a few months, and their symptoms will be closely monitored. Mesdopetam is a new treatment developed for managing complications of Parkinson's disease therapy, such as involuntary movements and psychosis.

Eligible Conditions

Dementia
Parkinson's Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to end of treatment (week 12)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to end of treatment (week 12)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to end of treatment (week 12) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia With Mesdopetam Compared to Placebo as Assessed With 24-hour Patient Home Diaries From Baseline to End of Treatment.

Secondary study objectives

Change From Baseline in Average Daily Hours of OFF-time (With Mesdopetam Compared to Placebo).

Change From Baseline in Mean Score of Disability Associated With ON-phase Dyskinesia Assessed With the Sum Score of Parts 1b and 4 of the Unified Dyskinesia Rating Scale (UDysRS), With Mesdopetam Compared to Placebo.

Change From Baseline in Mean Score of Motor Symptoms of PD Assessed With MDS-UPDRS Total Score of Part 2 (M-EDL) (With Mesdopetam Compared to Placebo)

+1 more